Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 29Neoplasms 4Renal Insufficiency 3Recurrence 3Neoplasms, Plasma Cell 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Immunoglobulin Light-chain Amyloidosis 2Blood Protein Disorders 2Purpura 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphadenopathy 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Hepatomegaly 1Hematologic Neoplasms 1Gastrointestinal Hemorrhage 1Diarrhea 1

Interventions

Cyclophosphamide 6Rituximab 3isatuximab 2fludarabine phosphate 2fludarabine 2durvalumab 2anlotinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Sunitinib 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Pemetrexed 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Lenalidomide 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Busulfan 2Bevacizumab 2130-nm albumin-bound paclitaxel 2ponatinib 1pomalidomide 1penpulimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms by Histologic Type × isatuximab × Clear all
NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡